Blockchain Registration Transaction Record

SureNano Science Targets Obesity Market with Novel GEP-44 Peptide

SureNano Science Ltd. (CSE:SURE) (OTCQB:SURNF) advances GEP-44 peptide for obesity, showing preclinical weight loss and glucose control. A potential non-injectable GLP-1 therapy.

SureNano Science Targets Obesity Market with Novel GEP-44 Peptide

This news matters because obesity and metabolic diseases are global health crises, and current GLP-1 therapies like Ozempic® are blockbusters but require injections. SureNano's GEP-44 peptide could offer a non-injectable alternative with better tolerability, potentially expanding access to millions of patients. If successful, it could disrupt the pharmaceutical market and provide new treatment options for those struggling with weight management and metabolic disorders.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0x949dce708d394bf66f9b697f23b8cef188b21fd540f2d3bed18d5fb602c35321
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintswimZLZq-20481fe4adbc9547f90bef80b06b25e6